First RSV vaccine for older adults is approved in Europe

Wise, Jacqui

doi:10.1136/bmj.p978

Cited by 8 publications

(3 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is important to prioritise this population for RSV prevention and vaccination programmes and priority setting. Two RSV vaccines, RSVPreF3-AS01E and RSVpreF, have been approved for use in older adults aged over 60 years by the Food and Drugs Administration (FDA) in the USA and the European Medicines Agency (EMA) [49][50][51]. Post-marketing surveillance to assess the likely impact of the introduction of RSV immunisation on preventing severe infections and hospitalisations in this population will be necessary in the next few years.…”

Section: Discussionmentioning

confidence: 99%

Burden of Respiratory syncytial virus (RSV) infection among adults in nursing and care homes: a systematic review

Osei-Yeboah,

Amankwah,

Begier

et al. 2024

Preprint

View full text Add to dashboard Cite

Background Older adults in nursing and care homes (NCHs) are vulnerable to severe respiratory syncytial virus (RSV) infection, hospitalisation, and death. This study aimed to gather data on RSV disease among older adults in NCHs and identify reported risk factors for RSV hospitalisation and case fatality. Methods The study protocol was registered in PROSPERO (CRD42022371908). We searched MEDLINE, EMBASE and Global Health databases to identify articles published between 2000 and 2023. Observational and experimental studies conducted among older adults in NCHs requiring assistive care and reporting RSV illness were included and relevant data were extracted. Results Of 18,690 studies screened, 32 were selected for full-text review and 20 were included. Overall, the number of NCH residents ranged from 42 to 1,459 with a mean age between 67.6 and 85 years. Attack rates ranged from 6.7 – 47.6% and annual incidence ranged from 0.5 – 14%. Case fatality rates ranged from 7.7 – 23.1%. We found similar annual incidence rates of RSV-positive acute respiratory infection (ARI) of 4,582 (95% CI: 3,259 – 6,264) and 4,785 (95% CI: 2,258 – 10,141) per 100,000 reported in two studies. Annual incidence rate of RSV-positive lower respiratory tract infection was 3,040 (95% CI: 1,986 – 4,454) cases per 100,000 adults. Annual RSV-ARI hospital admission rates were between 600 (95% CI: 190 -10,000) and 1,104 (95% CI: 350 – 1,930) per 100,000 person-years. Among all RSV disease cases, commonly reported chronic medical conditions included chronic obstructive pulmonary disease (COPD), heart failure, ischemic heart disease, coronary artery disease, hypertension, diabetes, kidney dysfunction, cerebrovascular accident, malignancies, dementia, and those with a Charlson comorbidity score > 6.5. Conclusion Data on RSV infection among NCH residents are limited and largely heterogeneous but document a high risk of illness, frequent hospitalisation, and high mortality. Preventive interventions, such as vaccination should be considered for this high-risk population. Nationally representative epidemiologic studies and NCH-based viral pathogen surveillance could more precisely assess the burden on NCH residents.

show abstract

Section: Discussionmentioning

confidence: 99%

Burden of Respiratory syncytial virus (RSV) infection among adults in nursing and care homes: a systematic review

Osei-Yeboah,

Amankwah,

Begier

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…On 3 May 2023, the U.S. Food and Drug Administration (FDA) granted approval to the first RSV vaccine in the world (AREXVY from GSK), specifically targeting individuals aged 60 and older, and it was approved by the European Union on 7 June 2023 [ 59 , 61 ]. The vaccine incorporates a stabilized form of the RSV F protein antigen [ 62 ].…”

Section: Discussionmentioning

confidence: 99%

Prospective Attitudes towards Respiratory Syncytial Virus (RSV) Vaccination: Validation of a Survey Instrument among Young Females in Jordan Pending Vaccine Authorization

Kherfan,

Sallam

2023

Vaccines

View full text Add to dashboard Cite

In May 2023, the U.S. FDA advisors endorsed Pfizer’s pregnancy-administered vaccine (branded ABRYSVO) to protect infants from respiratory syncytial virus (RSV) infection. Vaccination can reduce the burden of RSV-related respiratory disease, with previous studies showing its substantial medical and financial burden in Jordan. However, pregnant women may exhibit hesitancy to get vaccinated due to concerns about potential risks to themselves or their fetuses. This study aimed to assess the acceptance of the RSV vaccine among young females and identify the determinants influencing their decision using a newly constructed instrument. A survey instrument was developed and validated, comprising 26 items to measure RSV vaccine acceptance. A cross-sectional study design was employed, with data collection from a sample of females aged 18 to 45 residing in Jordan during 5–6 July 2023, using a convenient approach via an online distributed questionnaire. The final study sample comprised 315 respondents, with 67.6% who have heard of RSV before the study. If the vaccine was safe, effective, and provided freely, 70.2% showed willingness to get the RSV vaccine, 15.2% resisted, and 14.6% were hesitant. Principal component analysis identified six internally consistent sub-scales with the following suggested themes: Advice, Burden, Conspiracy, Dangers, Efficiency, and Fear, comprising 21 items collectively as assigned as the “ABCDEF” scale for RSV vaccine acceptance. RSV vaccine acceptance in this study was associated with the advice and fear constructs. The validated survey instrument successfully captured important determinants of RSV vaccine acceptance among young females. RSV vaccine promotion efforts should focus on the following: enhancing vaccine education, improving trust in healthcare institutions and providers, reducing burdens through resolving cost issues and focusing on the role of social support, addressing safety concerns, and tailoring communication strategies to effectively promote the benefits of the vaccine. These insights can inform public health policies and interventions aiming to promote RSV vaccination and mitigate the burden of RSV-related diseases among infants. Follow-up studies are recommended with pregnant women as the target group to assess their attitude towards RSV vaccination and to confirm the validity of the conceived ABCDEF survey instrument.

show abstract

“…The Medicines and Healthcare Products Regulatory Agency has authorised Arexvy, the first vaccine for preventing lower respiratory tract disease caused by respiratory syncytial virus (RSV) in over 60s. The move follows a recommendation for marketing authorisation of the vaccine by the European Medicines Agency in April 2. The UK agency’s decision is supported by data that found 82.6% efficacy against RSV from a phase 3 study published in the New England Journal of Medicine 3.…”

Section: Vaccinesmentioning

confidence: 99%

Seven days in medicine: 5-11 July 2023

2023

BMJ

View full text Add to dashboard Cite

First RSV vaccine for older adults is approved in Europe

Cited by 8 publications

References 3 publications

Burden of Respiratory syncytial virus (RSV) infection among adults in nursing and care homes: a systematic review

Burden of Respiratory syncytial virus (RSV) infection among adults in nursing and care homes: a systematic review

Prospective Attitudes towards Respiratory Syncytial Virus (RSV) Vaccination: Validation of a Survey Instrument among Young Females in Jordan Pending Vaccine Authorization

Seven days in medicine: 5-11 July 2023

Contact Info

Product

Resources

About